

Technical Data Sheet

Product Anti-Hu CD222 Purified

Cat. Number/Size **11-790-C100 0.1 mg** 

For Research Use Only.

Not for use in diagnostic or therapeutic procedures.

Antigen CD222
Clone MEM-240
Format Purified
Reactivity Human

Application FC (QC tested), IP, WB

Application details Flow cytometry: Extracellular and intracellular staining. Recommended dilution: 2-6 µg/ml.

Western blotting: non-reducing conditions. Recommended dilution: 1-2 µg/ml.

Isotype Mouse IgG1

Specificity The antibody MEM-240 recognizes an extracellular epitope between amino acids 698-1262 of CD222 (IGF2

receptor), a ubiquitously expressed 250 kDa multifunctional type I transmembrane protein. The majority of CD222 is found in the late endosomal/prelysosomal compartment, 5-10% in the plasma membrane and the

truncated (220 kDa) form of CD222 is present in human and bovine serum.

Other names IGF2R, MPR1, CIMPR, MPR300, M6P-R

Workshop HLDA VII; WS Code 70641

Immunogen Recombinant Vaccinia virus encoding CD222.

Entrez Gene ID 3482
Gene name IGF2R

NCBI Full Gene Name insulin like growth factor 2 receptorprovided

UniProt ID P11717

Concentration 1 mg/ml

Preparation Purified by protein-A affinity chromatography.

Formulation Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling Store at 2-8°C. Do not freeze.

Images and References www.exbio.cz

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Revision date: 2025-01-02